Investors seeking exposure to AI hardware should favor SK Hynix (000660.KS) over Micron Technology (MU) due to its dominant market leadership in high-bandwidth memory (HBM) and more attractive valuation.

In the expanding NeoCloud infrastructure space, IREN (IREN) presents a compelling buying opportunity, trading approximately 40% cheaper on a forward basis than rival Nebius Group (NBIS) following an overblown earnings pullback.

The recent 18% dip in Hims & Hers Health (HIMS) offers an attractive entry point to gain exposure to the booming GLP-1 market, as it trades up to 8x cheaper than pharmaceutical giants like Eli Lilly (LLY) ahead of major drug catalysts spanning 2026 to 2027.

MicroStrategy (MSTR) remains the premier high-conviction vehicle for amplified upside to Bitcoin (BTC) as institutional treasury adoption continues to lock up circulating supply.

Long-term investors should look past the post-Cybercab sell-off in Tesla (TSLA) and use the price drop to accumulate shares targeting autonomous fleet execution and cost-efficient manufacturing toward 2030 and beyond.

SK Hynix (000660.KS) & Micron Technology (MU)

• Both semiconductor memory makers saw a strong bounce despite broader market weakness, with SK Hynix gaining 8% and Micron rising 6% (moving back above $100).
• When comparing the two, SK Hynix presents a more attractive valuation:
  • SK Hynix trades at an Enterprise Value to Gross Profit over Revenue Growth (EV/GP/RG) ratio of 0.09.
  • SK Hynix is the established leader in high-bandwidth memory (HBM), whereas Micron holds a smaller market share in this specialized segment.
  • Micron has experienced a rapid run-up, gaining more than 8x over the past 52 weeks, making SK Hynix a comparatively safer valuation play.

Takeaways

• SK Hynix is favored over Micron as the better value play and market leader in high-bandwidth memory for AI hardware.

IREN (IREN) & Nebius Group (NBIS)

• Both companies operate in the rapidly expanding NeoCloud infrastructure sector, which benefits from an enormous total addressable market.
• A comparative analysis highlights a valuation gap between the two names:
  • IREN is approximately 40% cheaper on a forward-looking basis and roughly 4x cheaper on a trailing/backward-looking basis compared to Nebius.
  • Over the past 52 weeks, Nebius has run up 3.5x, while IREN has gained only 53%.
  • Negative market reactions to IREN's recent earnings call were likely overblown by retail sentiment and narrative-driven social media trading.

Takeaways

• IREN represents a significantly cheaper entry point than Nebius to gain exposure to the fast-growing AI cloud and high-performance computing infrastructure sector.

Hims & Hers Health (HIMS)

• Hims & Hers has pulled back 18% from its intra-month high and 14% over the past month, moving downward without any negative company-specific news.
• The stock currently trades in tandem with large-cap GLP-1 pharmaceutical makers like Eli Lilly (LLY) and Novo Nordisk (NVO), which have also experienced recent stagnation.
• Long-term growth catalysts remain strong:
  • The anticipated approval of next-generation weight-loss peptides like Retatrutide (potentially around late 2027) is expected to end compounding exemptions, shifting large consumer volumes to branded distribution platforms like HIMS.
  • Upcoming approvals for multiple other peptide treatments in 2026–2027 could provide substantial runway.
• Hims & Hers trades at an EV/GP/RG ratio of 0.1 and maintains a Rule of 40 score of 46, making it 5x to 8x cheaper than traditional pharmaceutical leaders like Eli Lilly and Novo Nordisk.

Takeaways

• The recent dip in HIMS is driven by sector-wide sentiment rather than deteriorating fundamentals, offering long-term upside as it expands into telehealth distribution for advanced GLP-1 and peptide therapies.

MicroStrategy (MSTR) & Bitcoin (BTC)

• MicroStrategy displayed relative strength by outperforming Bitcoin on a day when Bitcoin pulled back 2.5%.
• This outperformance signals that MicroStrategy did not run an at-the-market (ATM) share offering during the session.
• Corporate balance sheet adoption and treasury accumulation strategies continue to lock up fixed-supply Bitcoin, supporting long-term value for direct holders and proxy equities alike.

Takeaways

• MicroStrategy remains a high-beta vehicle for Bitcoin exposure, benefiting directly from institutional treasury accumulation models that reduce the circulating supply of BTC.

Tesla (TSLA)

• Tesla experienced a "sell the news" pullback, dropping 5.9% post-event and giving back all of its prior 5.4% pre-event gains.
• The Cybercab event highlighted several key manufacturing and engineering advancements:
  • Implementation of the "unboxed" manufacturing process designed to drastically reduce production costs and increase build speed.
  • Electric drive motors engineered completely free of rare earth elements.
• The sell-off was triggered by Wall Street's frustration over the lack of concrete timelines, quantitative rollout metrics, and city-by-city scaling schedules for the Robotaxi fleet.

Takeaways

• High volatility around major media events is standard for TSLA. Long-term investors focused on autonomy and scalable manufacturing should avoid short-term event trading and maintain a multi-year investment horizon (toward 2030 and beyond).